Israeli drug development company Can-Fite BioPharma Ltd. (TASE:CFBI), announced today that it completed pre-clinical trials for the testing of the metabolism and excretion of its flagship drug CF101 for the treatment of rheumatoid arthritis. The trials are being conducted as part of the preliminary process for Phase IIb trials that are due to being in the near future.
The latest trials found that CF101 does not break down in the liver and is excreted in its entirety in urine discharges, thereby reducing the development of side effects. The drug’s stability in the liver is likely to support its development for use in treating liver-related conditions, such as cirrhosis, liver cancer and hepatitis B and C.
The trials were coordinated with the US Food and Drug Administration (FDA), by the company’s clinical R&D team, including clinical development and regulation experts with many years experience of drug development in the US.
Can-Fite CEO Professor Pnina Fishman said the findings from the latest trials support the company’s development program for CF101’s promotion as a treatment for rheumatoid arthritis under the framework of Phase II trials. She added that they would also serve the promotion of CF101 as a treatment for other indications, as well as the basis of new drug developments, should the company decide to pursue them.
Published by Globes [online], Israel business news - www.globes.co.il - on June 14, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006